首页> 美国卫生研究院文献>Molecules >Evaluation of the Bioactivity of Novel Spiroisoxazoline Type Compounds against Normal and Cancer Cell Lines
【2h】

Evaluation of the Bioactivity of Novel Spiroisoxazoline Type Compounds against Normal and Cancer Cell Lines

机译:评价新型螺异恶唑啉型化合物对正常和癌细胞系的生物活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this study was to investigate the in vitro cellular activity of novel spiroisoxazoline type compounds against normal and cancer cell lines from lung tissue (Hs888Lu), neuron-phenotypic cells (SH-SY5Y), neuroblastoma (SH-SY5Y), human histiocytic lymphoma (U937), lung cancer (A549), and leukaemia (HL-60). Our bioassay program revealed that the spiroisoxazoline type compounds show cytotoxicity only in lymphoma cell lines, which is in contrast with the pyrrolidine precursor of these spiroisoxazoline compounds, where significant cytotoxicity is seen in all normal and cancer cell lines. These data suggest a tumour-specific mechanism of action. In addition these data also show that spiroisoxazoline compounds are non-toxic in the human neuron-phenotypic neuroblastoma SH-SY5Y cell line, and furthermore that they might protect cells from neurodegenerative disease.
机译:这项研究的目的是研究新型螺异恶唑啉型化合物对来自肺组织(Hs888Lu),神经元表型细胞(SH-SY5Y),神经母细胞瘤(SH-SY5Y),人类组织细胞的正常和癌细胞系的体外细胞活性淋巴瘤(U937),肺癌(A549)和白血病(HL-60)。我们的生物测定程序表明,螺旋异恶唑啉型化合物仅在淋巴瘤细胞系中显示出细胞毒性,这与这些螺旋异恶唑啉化合物的吡咯烷前体相反,后者在所有正常细胞和癌细胞系中均具有明显的细胞毒性。这些数据提示了肿瘤特异性的作用机制。此外,这些数据还表明,螺异恶唑啉化合物在人神经元-表型神经母细胞瘤SH-SY5Y细胞系中是无毒的,此外,它们还可以保护细胞免受神经退行性疾病的侵害。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号